Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Tips voor een nieuwe beleggingsliefde.....

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Tips voor een nieuwe beleggingsliefde.....

235 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 12 »» | Laatste | Omlaag ↓
  1. [verwijderd] 13 november 2010 18:22
    Echter 3 direkteuren en een CEO kochten onlangs uit de 4,5 Mn aandelen-emissie voor $ 3,50 p/a gezamelijk voor $350.000 aan aandelen PIP
    Zij hebben ze alvast.
    ------------------------------------------------------------------

    Ze konden moeilijk anders imo.
    Per 30-06 jl. een negatief EV van $ 10 mio.
    Technisch failliet dus op dat moment.
    Aandelen bijdrukken was de enige oplossing.
    En dan vraagt de Board altijd aan het MT om mee te doen.
    Altijd. To show their commitment.
    Trouwens 100.000 pcs op de 4.300.000 is niet overdreven veel.
    Ze hebben even met de emissie gewacht, slim.

    Na emissie zal het EV op $ 5 mio staan, in de plus.
    4,3 mio aandelen erbij, maakt totaal 34 mio aandelen, effe grof.

    Intrinsieke waarde per aandeel $ 0,14 á $ 0,15.

    En dat mag je kopen voor $ 3,10.

    Huiverrrr en Bibberrrr.

    Dan toch liever BNC.
  2. [verwijderd] 13 november 2010 18:30
    PharmAthene, Inc. (PIP) reported third quarter 2010 net loss of 14 cents per share beating the Zacks Consensus Estimate of net loss of 19 cents per share and up 72% from the same quarter prior year.

    Net revenue decreased 8.8% from year ago quarter to $6.2 million, below the Zacks Consensus Estimate of $8 million.

    Factors responsible for the revenue decline included the completion of activities under the company’s existing Department of Defence contract, which concluded in third quarter of previous year and was partially offset by funding from the Defence department in the second and third quarters of 2010. Also, overall reduced activities and completion of all activities in the plague program early this year led to a revenue drop.

    Both Research and Develepment (R&D) expenses and General and Administrative (G&A) expenses reduced from prior year quarter significantly.

    R&D expenses dropped 21.5% to $6.2 million and G&A expense decreased 48.4% to $3.2 million compared to the prior-year quarter.

    Overall decreased activity levels, particularly the completion of various programs, including the plague program, resulted in the decline of the R&D outlays. G&A expenses decreased due to cost reduction in personnel expenses, professional services and non cash stock-based compensation.

    At the end of the quarter, the company had cash and cash equivalents of $2.7 million and no long-term debt. This month PharmAthene also completed a registered public offering of 4.3 million shares at a price of $3.50 per share and generated approximately $14.1 million of proceeds, before expenses. Management expects that the ongoing cost controls and other measures will leave the company well capitalized for the following quarters.

    Zacks Consensus Estimate for the quarter had remained stable in the run up to the earnings release, but estimates for the current and next year have gone up in the last 30 days. Estimates for current year went up to net loss of 81 cents from 85 cents as 2 analysts raised their estimates. One positive revision for next year resulted in a rarrowing of the loss estimate for next year to 61 cents from 63 cents per share.

    We currently have a Zacks #2 Rank for PharmAthene, which translates to a Buy rating on short term basis.

  3. [verwijderd] 13 november 2010 18:38
    PharmAthene Reports Third Quarter 2010 Financial and Operational Results
    November 11, 2010 4:00 PM ET
    PharmAthene Reports Third Quarter 2010 Financial and Operational Results
    Recent Financing Strengthens PharmAthene's Balance Sheet
    PR Newswire

    ANNAPOLIS, Md., Nov. 11, 2010

    Recent Financing Strengthens PharmAthene's Balance Sheet

    ANNAPOLIS, Md., Nov. 11, 2010 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the third quarter and nine months ended September 30, 2010.

    For the third quarter of 2010, PharmAthene recognized revenues of $6.2 million compared to $6.8 million in the same period of 2009. For the nine months ended September 30, 2010 and 2009, respectively, PharmAthene recognized revenues of $14.1 million and $20.4 million. Revenues for the most recent quarter and nine months ended September 30, 2010 consisted primarily of contract funding from the U.S. government for the development of SparVax™, Valortim®, and Protexia®.

    The decline in revenue in the third quarter and first nine months of 2010 compared to 2009 is attributable to (i) the completion of activities under the Company's existing Department of Defense (DoD) contract for Protexia®, which concluded in the third quarter of 2009, partially offset by modest funding from the DoD for this program in the second and third quarters of 2010, and (ii) reduced activity in the Company's Valortim® program, (iii) the completion of all activities in the Company's plague program during early 2010, (iv) partially offset by increased revenues under the Company's SparVax™ program.

    Research and development expenses were $6.2 million and $7.9 million for the quarter ended September 30, 2010 and 2009, respectively. Research and development expenses were $17.1 million and $23.9 million for the nine months ended September 30, 2010 and 2009, respectively.

    Research and development expenses decreased in the third quarter and first nine months of 2010 compared to the prior year period as a result of decreased activity in the Company's Valortim® anthrax anti-toxin and chemical nerve agent bioscavenger programs, as well as the completion of all activities in the Company's plague program, partially offset by increased activity under the SparVax™ anthrax vaccine program. In addition, the decrease in research and development costs for the nine months ended September 30, 2010 also reflects the inclusion of a one-time $3.0 million Avecia termination fee in the second quarter of 2009.

    Expenses associated with general and administrative functions were $3.2 million in the third quarter of 2010 compared to $6.2 million in the same period in 2009. Expenses associated with general and administrative functions were $12.6 million and $15.8 million for the nine months ended September 30, 2010 and 2009, respectively.

    General and administrative expenses decreased approximately $3.0 million for the three months ended September 30, 2010, and approximately $3.2 million for the nine months ended September 30, 2010, as compared to the prior year periods. These decreases were the net result of a corporate wide cost reduction program which included reductions in personnel expenses, professional services, and non cash stock-based compensation.

    For the third quarter of 2010, PharmAthene's net loss attributable to common shareholders was $4.3 million or $0.14 per share, compared to $14.0 million or $0.50 per share in the same period of 2009. For the nine months ended September 30, 2010, the Company's net loss attributable to common shareholders was $18.7 million or $0.62 per share, compared to $26.6 million or $0.97 per share in the same period of 2009.

    As of September 30, 2010, the Company had cash and cash equivalents, restricted cash, short-term investments, and US government account receivables and other receivables totaling approximately $11.5 million as compared to $23.2 million at December 31, 2009. In November 2010, PharmAthene completed a registered public offering of approximately 4.3 million shares of the Company's common stock at a price to the public of $3.50 per share, which generated estimated net proceeds of $14.1 million before expenses. Simultaneously with the closing, certain of the Company's 10% senior convertible note holders converted their notes into an aggregate of approximately 3.4 million shares of the Company's common stock.

    "This financing, in combination with the conversion of certain of our senior convertible notes, has significantly strengthened the Company's cash position and reduced our current debt. Combined with our ongoing expense reduction plan and streamlined operations, we believe PharmAthene is now well capitalized through the balance of 2011," commented Eric I. Richman, President and Chief Executive Officer of PharmAthene.

    Conference Call and Webcast Information

    PharmAthene management will be hosting a conference call to discuss the Company's third quarter 2010 financial results. The call is scheduled to begin at 4:30 p.m. Eastern Time on Thursday, November 11, 2010, and is expected to last approximately 30 minutes. The dial-in number within the United States is 800-299-0148. The dial-in number for international callers is 617-801-9711. The participant passcode is 56373544.

    A replay of the conference call will be available beginning at approximately 7:30 p.m. Eastern Time on November 11, 2010 until approximately 11:59 p.m. Eastern Time on December 11, 2010. The dial-in number to access the reply from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 23749330.

    The conference call will also be webcast and can be accessed from the company's website at www.PharmAthene.com. A link to the webcast may be found under the Investor Relations section of the website.

  4. [verwijderd] 13 november 2010 19:07
    Na het verlies van $ 4,3 mio in Q3 is het EV weer gedaald tot $ 0,7 mio.
    EV per aandeel per 30 september: $ 0,02.
    Daar ga je toch geen $ 3,10 voor neerleggen, of wel?
    De vorige emissie, die een verwatering gaf van 15%, zal imo nog worden gevolgd door nieuwe emissies.
    Want winst maken is er in de komende paar jaar niet bij.
    En met een negatief EV kan je beter wat anders gaan doen.
    Voordat ze je uit de notering halen.
    En dat ze overgenomen worden zie ik ook niet zo snel gebeuren.
  5. flosz 14 november 2010 14:49
    quote:

    wilb52 schreef:

    Uranium Resources
    Blue Sky Mine …….
    Kernwapens/kernreactoren/ munitie
    Uraniummijnen->gevaar(vervuiling/ziekte) voor lokale bevolkingsgroepen (oa Indianen VS/ Aboriginals Australië/ Toearegs Niger/ Inuit Canada)
    www.mo.be/node/18571
    www.indians.nu/index.php?option=com_c...
    uranium-news.com/2010/09/04/deplorabl...
    www.orionmagazine.org/index.php/artic...
    www.nytimes.com/2009/07/27/us/27navaj...
    www.umich.edu/~snre492/sdancy.html
    www.youtube.com/watch?v=xcjsvH3cCig
  6. flosz 14 november 2010 15:58
    quote:

    laatookuwinstinctsturen schreef:

    PharmAthene
    Crucell & Pharmathene:
    Pharmathene, Inc. Dec. 2009 PER.C6 Undisclosed protein Pre-clinical
    hugin.info/132631/R/1401132/356214.pdf

    Crucell & miltvuur…
    IQ Corporation
    imode.iex.nl/forum/topic.asp?forum=22...
    imode.iex.nl/forum/topic.asp?forum=22...
    imode.iex.nl/forum/topic.asp?forum=22...
    imode.iex.nl/forum/topic.asp?forum=22...
    imode.iex.nl/forum/topic.asp?forum=22...
    Survival rate up to 100% for late stage treatment of Anthrax infections
    www.iqtherapeutics.nl/
  7. [verwijderd] 15 november 2010 11:32
    verdiep je eens in Immunovaccine, www.imvaccine.com/, bizarre techniek en al deals met Pfizer voor dieren. Hebben een vaccin tegen kanker dat werkt in muizen en de tumor doet verdwijnen!!!!

    recent emissie gedaan op CAD 1,- en doen nu 0.85. Mega veel materiaal beschikbaar dus lees je in.
  9. [verwijderd] 15 november 2010 15:27
    Tophound en Flosz Bedankt dat u uw bevindingen hier heeft willen delen.
    een gewaarschuwd mens telt voor twee.
    Zo had deze amateur er nog niet naar gekeken voor wat betreft het eigen vermogen
    Ik zal extra voorzichtig zijn.

    IQ Therapeutics heeft ism Texas Medical Branch een anthraxvaccin in een ver gevorderd stadium van ontwikkeling dat 100% genezing biedt voor konijnen, zelfs 48 uur na besmetting.
    PIP ontving een contract van $78,4 Mn van BARDA voor de verdere ontwikkeling van haar 2e generatie Anthraxvaccin (Sparvax) voldoende tot 2012
    Rond augustus 2011 maakt PIP kans op een aanvullend contract t.w.v. $100 MN voor Sparvax voor een periode van 3 of 4 jaar.
    Pip komt in aanmerking voor totaal 3 contracten in 2011 met een potentiële waarde van $250 tot $300 Mn die tezamen met bestaande contracten kunnen leiden tot een cashflow Break Even tot zelfs een bescheiden cashflow in 2011


    Antwoord op mijn vraag:
    [Dear Louis,
    Our apologies, but we have never disclosed which if any of our products are being developed using the PER.C6 technology. We appreciate your interest in the company].

    Sinds december heeft PIP een PER.C6 licentie.
    De 2e generatie rPA Anthrax SPARVAX wordt mogelijk sinds december verder ontwikkeld op PER.C6
    The rPA contract modification was announced via a Special Notice (Solicitation Number: HHSO100200900103C) rPA Anthrax Vaccine Advance Development, issued by HHS on December 29, 2009. PharmAthene could receive up to approximately $61 million during the base period of the modification, assuming that all milestones are achieved, and up to an additional $17.4 million, if the government exercises all options under the modification. The original development contract for rPA vaccine (N01-Al-30052) was awarded in 2003 and transferred to BARDA on April 1, 2009.
    PIP heeft sinds december 2009 een PER.C6-licentie (Flosz) en heeft ook plannen om gebruik te maken van disposables

    30 Januari dient het vooronderzoek van de rechtszaak tegen SIGA
    Pip verwacht elk moment een opinie van de rechter betreffende deze rechtszaak
    Van de 2,3 Mrd die SIGA ontving voor de pokkenorder verwacht PIP en belangrijk deel te kunnen vorderen.

    E.e.a. ook vernomen uit een Half uur durende CC
    ir.pharmathene.com/phoenix.zhtml?p=ir...
    Mijn kennis van mijn Engels schiet hier te kort om alles precies te begrijpen wat er gezegd wordt.

    Het aandeel stond, ten tijde van de emissie van 4,3 MN aandelen voor $ 3,50 p/a, rond de $4 10.
    Een gebruikelijke korting dus van 15%
    Het management nam voor $350.000 = 2,32% deel aan deze emissie
    De reden voor de deelname van het MT kan dan om verschillende redenen zijn ontstaan.
    1) Ter ondersteuning van de emissie.
    2) Omdat er meerdere mogelijkheden zijn om in 2011 een cashflow te realiseren.

    Met vriendelijke groet

    Louis
  10. [verwijderd] 15 november 2010 16:17
    -Dr. Gary Weber presents information about cattle vaccine to reduce shedding of E. coli O157-

    BELLEVILLE, ON, Nov. 15 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that its President of Bioniche Food Safety in the U.S. presented an invited paper to the U.S. Animal Health Association (USAHA)'s Food and Feed Safety Committee meeting this weekend. Dr. Gary Weber's presentation, "Opportunities to Reduce the Risk of Shedding E. coli O157 by Cattle: Implications for Beef Safety, the Environment and Public Health", was part of a day-long session entitled, "E. coli O157:H7 Update: Research, Interventions and Epidemiology".

    Dr. Weber's presentation focused on the incidence of E. coli O157:H7 in cattle (the primary reservoir) and its resulting impact on human health, pointing out the distinct seasonal profile and relationship between shedding of E. coli O157:H7 by cattle, beef contamination, and human illness associated with various food sources and human contact with livestock.

    Dr. Weber pointed out that, historically, the peak shedding period for E. coli O157:H7 in cattle in the United States is June, with the corresponding peak of the pathogen in ground beef and human illness in July. In addition, 74% of produce outbreaks associated with E. coli O157:H7 between 1991 and 2002 occurred between July and October. Further E. coli O157:H7 human illness outbreaks have been associated with contact with animals at fairs, exhibitions and petting zoos, many of which are seasonal events.

    Dr. Weber summarized that a reduction in the peak shedding period for E. coli O157:H7 by cattle, as observed from April through September in the U.S., to that observed from October through March, would correspondingly reduce the prevalence of E. coli O157:H7 in beef and reduce associated human illness. Evidence suggests that post-harvest (in-plant) interventions are currently capable of controlling the risk posed by E. coli O157:H7 contamination of beef from October through March. However, these intervention systems appear to be overloaded as a result of the seasonal increase in shedding from April through September. Research indicates vaccination of cattle would reduce this seasonal burden. In addition, if there was widespread adoption of vaccination, it is reasonable to expect the reduction in shedding of E. coli O15:H7 by cattle would correspond to a reduction in human illness associated with produce, water and contact with livestock, particularly cattle, as well as other species.

    Bioniche Life Sciences Inc. has developed and licensed (in Canada) the world's first vaccine to reduce the shedding by cattle of E. coli O157. Econiche™ received full licensing approval from the Canadian Food Inspection Agency (CFIA) in October, 2008 and is available for unrestricted use by Canadian cattle producers and their veterinarians. The United States Department of Agriculture (USDA) cleared the path for a conditional license for the vaccine in February, 2008, and the Company is awaiting issuance of that license.

    Econiche™ is a Canadian discovery developed by Bioniche Life Sciences Inc. The vaccine has the potential to significantly reduce the amount of E. coli O157 shed into the environment by beef and dairy cattle. This organism does not cause illness in cattle, however, cattle are the primary reservoir for it. Most strains of E. coli are harmless but some, like O157, can cause severe illness and even be fatal when ingested by humans from contaminated meat, vegetables or water. Vaccination of cattle with Econiche can help reduce the risk of food and waterborne contamination with E. coli O157.

    Econiche is manufactured in the Bioniche production facility in Belleville, Ontario, where a $25-million expansion is taking place, supported by the Ontario and Canadian governments. The expansion is expected to be completed by the end of March, 2011.

  13. [verwijderd] 16 november 2010 12:44
    Ha Flosz...alweer? IMV is een schitterend bedrijf en ik probeer alleen de awareness te vergroten onder NL beleggers. Ik ben een biotech kenner en als ik een parel zie, probeer ik dat te delen met iedereen. Nogmaals, iedereen moet zelf zijn onderzoek doen en dat kan prima want IMV biedt een schat aan info aan op de website. Dus me niet meteen afbranden als een spammer want dat ben ik niet.
  14. [verwijderd] 16 november 2010 14:07
    Ik heb een beetje een tic wat dat betreft, maar je zou toch echt eens naar de Balans moeten kijken.
    Het EV per 30/6 bedroeg $ 460.000 !
    Wat zou het salaris van de CEO zijn ?
    Structureel verlieslatend.
    Nog een klein tikkie en ook IMV is technisch failliet.
    Aantal aandelen: Bijna 46 miljoen.
    De intrinsieke waarde per aandeel bedraagt dus 1ct, daar kan niet veel meer vanaf.
    Wordt verhandeld voor 85 cts.
    Met negatieve uitschieters op 1 dag naar 70 cts.
    Een rollercoaster dus.
    Vanaf blijven, is mijn advies.
  16. [verwijderd] 16 november 2010 14:55
    quote:

    Potjer schreef:

    lekkere visie.... volgens mij was crxl ook jaren verliesgevend? Enieways, je hebt recht op je mening en ik zal jullie cru believers lekker alleen laten, over een jaar spreken we elkaar
    klopt, echter CruSELL had WEL geld in kas,
    en niet zo'n beetje ook!
    Destijds op ca 1.40 euri, was het ook voor mij de reden om in te stappen
    aangezien er 3.5 euri in kas zat!
    That's different cook.
  17. [verwijderd] 16 november 2010 16:49
    Ik zit al een halfjaartje naar SCLN te staren, er is een hoop gezeur geweest afgelopen zomer, class actions en zo wegens manipulatie van cijfers o.a.

    Het hele verhaal staat hier:

    www.prnewswire.com/news-releases/shar...

    Koers stortte in elkaar op 10 aug., van $ 3,50 naar $ 2,40.
    Staat nu weer vrij stabiel rond de $ 3,70.

    Goede productlijn, net een beetje winstgevend --> EV staat niet onder druk, EV is $ 1,44 p/a.

    Ik koop ze vanavond, met enige huiverrr, dat wel. Meteen een S/L eronder van $ 2,95.

    Meer weten?

    SciClone Pharmaceuticals, Inc. (SciClone ) is a global specialty pharmaceutical company. It has a product portfolio of therapies for cancer and infectious diseases. SciClone has in-licensed two products that are part of this international commercial growth strategy, DC Bead and ondansetron RapidFilm. Its DC Bead product candidate is a treatment for liver cancer, which is approved in 40 countries worldwide, including Europe and the United States. The Company has commercialization rights for ondansetron RapidFilm product in China and Vietnam. Ondansetron RapidFilm is an oral thin film formulation of ondansetron used to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy and surgery. Its clinical development is focused on its portfolio of product candidates for cancer and infectious diseases and includes SCV-07 and thymalfasin. SCV-07 is being developed for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck and for the treatment of hepatitis C virus (HCV). Thymalfasin is being developed in an ongoing clinical trial for improvement of Influenza A (H1N1) vaccination in immuno-compromised patient populations and for stage IV melanoma.

    In 2009, its partner Sigma-Tau Finanziaria, S.p.A. (Sigma-Tau) initiated a study in Italy to evaluate thymalfasin’s ability to improve immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria from Novartis. The study, being conducted in hemodialysis patients reached full enrollment after two days, and in 2010, it reported preliminary results from this study regarding ZADAXIN’s ability to improve response to H1N1 vaccine. ZADAXIN is approved in over 30 countries, primarily in Asia, Eastern Europe, the Middle East and Latin America. It sells ZADAXIN in various international markets through its wholly owned subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

    SciClone’s drug candidate SCV-07 (gamma-D-glutamyl-L-tryptophan) is a small molecule, which stimulates the immune system, possibly through inhibition of STAT3 signaling, and the resulting effects on T-helper 1 cells. The Company has conducting a phase II clinical trial of SCV-07 for the delay to onset and severity of severe oral mucositis in subjects receiving chemoradiation therapy for the treatment of cancers of the head and neck. This study was conducted at 21 centers in the United States and includes approximately 20 patients in each of the three treatment cohorts. ZADAXIN is SciClone’s synthetic preparation of thymalfasin, referred to as thymosin alpha 1, a thymic peptide, which circulates in the blood naturally and is instrumental in the immune response to certain cancers and viral infections.
  18. [verwijderd] 16 november 2010 16:55
    En dan nog BNC, goede kandidaat opvolger.
    Verderop in een apart draadje.
    Doet nog weinig sinds de aankoop een paar weken geleden, een paar honderd dollares op verdiend, maar wat moet je daar mee tegenwoordig, hoewel het zijn Maple Leaves, die worden (nog) niet kwantitatief vergemakkelijkt.
235 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 12 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 914,74 +0,46%
EUR/USD 1,0838 +0,13%
FTSE 100 8.358,02 -0,15%
Germany40^ 18.717,20 +0,20%
Gold spot 2.355,59 -0,96%
NY-Nasdaq Composite 16.801,54 -0,18%

Stijgers

bpost
+1,37%
Ontex
+1,32%
EVS
+1,18%
UCB
+1,18%
Gimv
+0,97%

Dalers

Ackerm...
-3,52%
Aedifica
-1,89%
Orange...
-1,60%
Elia
-1,60%
Umicore
-1,31%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!